Spurt Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.20 M
- Paid Up Capital ₹ 0.20 M
- Company Age 16 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth -16.52%
- Profit Growth 37.78%
- Ebitda -42.25%
- Net Worth 28.69%
- Total Assets -18.91%
About Spurt Pharmaceuticals
Spurt Pharmaceuticals Private Limited (SPPL) is a Private Limited Indian Non-Government Company incorporated in India on 10 July 2008 and has a history of 16 years and six months. Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.20 M and a paid-up capital of Rs 0.20 M, as per Ministry of Corporate Affairs (MCA) records.
Sweety Yadav, Sunit Kumar, and Pankaj Kumar serve as directors at the Company.
Company Details
-
Location
Delhi, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24232DL2008PTC180774
-
Company No.
180774
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
10 Jul 2008
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Spurt Pharmaceuticals?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sunit Kumar
|
Director | 01-Jul-2009 | Current |
|
Sweety Yadav
|
Director | 10-Jul-2008 | Current |
|
Pankaj Kumar
|
Director | 26-Nov-2015 | Current |
Financial Performance of Spurt Pharmaceuticals.
Spurt Pharmaceuticals Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 16.52% decrease. The company also saw a substantial improvement in profitability, with a 37.78% increase in profit. The company's net worth Soared by an impressive increase of 28.69%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Spurt Pharmaceuticals?
In 2019, Spurt Pharmaceuticals had a promoter holding of 75.00% and a public holding of 25.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Biolife Sciences Impex Private LimitedSweety Yadav and Sunit Kumar are mutual person
-
Biolife Sciences (Opc) Private Limited
Sweety Yadav and Sunit Kumar are mutual person
-
Rewal Infocon Services Private Limited
Sweety Yadav and Sunit Kumar are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Spurt Pharmaceuticals?
Unlock and access historical data on people associated with Spurt Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Spurt Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Spurt Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
